Enterprise Therapeutics
is an England drug discovery company that researches and develops novel therapies for the treatment of respiratory diseases... Read moreEnterprise Therapeutics
is an England drug discovery company that researches and develops novel therapies for the treatment of respiratory diseases... Read more
News
May 13, 2026
Clinical Trials Arena
Enterprise Therapeutics: Enterprise's Phase II trial of ETD001 meets primary endpoint in pwCF
May 12, 2026
OINDPnews
Enterprise Therapeutics: Enterprise Therapeutics says Phase 2 trial of ETD001 inhaled ENaC blocker for CF met its primary endpoint
Dec 09, 2025
PharmaTimes
Enterprise Therapeutics: Enterprise Therapeutics publishes results of phase 1 study of ETD001
Nov 19, 2024
StreetInsider
Press Release: Enterprise Therapeutics : Enterprise Therapeutics Publishes on Medicinal Chemistry of ETD001, a Novel Inhaled ENaC Blocker for Treatment of Cystic Fibrosis
Sep 26, 2024
Manufacturing Chemist
Enterprise Therapeutics: Enterprise Therapeutics bags RPD designation from the FDA for cystic fibrosis therapy
Jun 12, 2024
Business Wire
Press Release: Enterprise Therapeutics : Enterprise Therapeutics Publishes Preclinical Profile of ETD001, a Novel Inhaled ENaC Blocker
Jan 30, 2024
FinSMEs
Enterprise Therapeutics: Enterprise Therapeutics Closes 26M Series B Follow-on Financing
Jan 30, 2024
European Biotechnology
Enterprise Therapeutics: 26m for Cystic Fibrosis Drug Trial
Jan 29, 2024
Endpoints News
Enterprise Therapeutics: Exclusive: UK biotech raises $33.1M to test CF drug that could work on top of standard of care
Jun 14, 2021
MarketScreener
Enterprise Therapeutics: Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001
Enterprise Therapeutics Competitors
1
2
3
4
5
6
7
8
9
10